Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

April 29, 2024

Study Completion Date

January 27, 2025

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

ARV-110

"Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A"

Trial Locations (54)

10065

Clinical Trial Site, New York

22903

Clinical Trial Site, Charlottesville

32003

Clinical Trial Site, Fleming Island

32117

Clinical Trial Site, Daytona Beach

32159

Clinical Trial Site, The Villages

32605

Clinical Trial Site, Gainesville

32701

Clinical Trial Site, Altamonte Springs

32763

Clinical Trial Site, Orange City

32778

Clinical Trial Site, Tavares

32792

Clinical Trial Site, Winter Park

32806

Clinical Trial Site, Orlando

32960

Clinical Trial Site, Vero Beach

33401

Clinical Trial Site, West Palm Beach

33414

Clinical Trial Site, Wellington

33511

Clinical Trial Site, Brandon

33607

Clinical Trial Site, Tampa

33705

Clinical Trial Site, St. Petersburg

33761

Clinical Trial Site, Clearwater

33770

Clinical Trial Site, Largo

33908

Clinical Trial Site, Fort Myers

33939

Clinical Trial Site, Cape Coral

33980

Clinical Trial Site, Port Charlotte

34102

Clinical Trial Site, Naples

34135

Clinical Trial Site, Bonita Springs

34211

Clinical Trial Site, Bradenton

34236

Clinical Trial Site, Sarasota

34292

Clinical Trial Site, Venice

34461

Clinical Trial Site, Lecanto

34474

Clinical Trial Site, Ocala

34608

Clinical Trial Site, Spring Hill

34655

Clinical Trial Site, New Port Richey

34994

Clinical Trial Site, Stuart

37055

Clinical Trial Site, Dickson

37066

Clinical Trial Site, Gallatin

37067

Clinical Trial Site, Franklin

37075

Clinical Trial Site, Hendersonville

37076

Clinical Trial Site, Hermitage

37090

Clinical Trial Site, Lebanon

37129

Clinical Trial Site, Murfreesboro

37160

Clinical Trial Site, Shelbyville

37167

Clinical Trial Site, Smyrna

37211

Clinical Trial Site, Nashville

48201

Clinical Trial Site, Detroit

60611

Clinical Trial Site, Chicago

68130

Clinical Trial Site, Omaha

70112

Clinical Trial Site, New Orleans

84112

Clinical Trial Site, Salt Lake City

89169

Clinical Trial Site, Las Vegas

90095

Clinical Trial Site, Los Angeles

92868

Clinical Trial Site, Orange

94158

Clinical Trial Site, San Francisco

97239

Clinical Trial Site, Portland

06510

Clinical Trial Site, New Haven

02114

Clinical Trial Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Arvinas Inc.

INDUSTRY

NCT03888612 - Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter